AGENTIX Corp

AGENTIX Corp is a clinical-stage biotechnology company based in New York, focused on developing a comprehensive suite of science-driven biopharmaceuticals targeting the endocannabinoid system to address various metabolic diseases, including Type 2 Diabetes Mellitus, chronic obesity, and nonalcoholic fatty liver disease. The company has secured exclusive licensing agreements with the National Health Research Institute and the Research Triangle Institute International to enhance its innovative product pipeline.

With a commitment to advancing consumer wellness and pharmaceutical products, AGENTIX aims to leverage proprietary cellular delivery technology and newly created molecules that specifically interact with endocannabinoid receptors for metabolic regulation and other clinical applications. The experienced management team and scientific advisors are dedicated to ensuring efficient product development and regulatory compliance to position the company for future growth and profitability.

Generated from the website